Company Description
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.
It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies.
The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024.
Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jan 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Nadim Ahmed |
Contact Details
Address: One Main Street, Suite 1350 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 410 4650 |
| Website | cullinantherapeutics.com |
Stock Details
| Ticker Symbol | CGEM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $21.00 |
| CIK Code | 0001789972 |
| CUSIP Number | 230031106 |
| ISIN Number | US2300311063 |
| Employer ID | 81-3879991 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nadim Ahmed | President, Chief Executive Officer and Director |
| Mary Kay Fenton CPA | Chief Financial Officer |
| Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder, Chief Scientific Advisor and Chairman of Scientific Advisory Board |
| Dr. Jennifer Michaelson Ph.D. | Chief Scientific Officer |
| Nicholas Smith | Head of Investor Relations |
| Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
| Steve Andre | Chief Human Resources Officer |
| Dr. Corinne Savill Ph.D. | Chief Business Officer |
| Rose Weldon | Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2026 | ARS | Filing |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |
| Mar 5, 2026 | 144 | Filing |
| Mar 4, 2026 | SCHEDULE 13G | Filing |